Poseida Therapeutics
Poseida Therapeutics was a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies and gene editing technologies for hematologic malignancies, solid tumors, autoimmune diseases, and genetic disorders, acquired by Roche in 2025.
- Company typePrivate
- Founded2014
- HeadquartersSan Diego, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Poseida Therapeutics does
Poseida Therapeutics was a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies and gene editing technologies for hematologic malignancies, solid tumors, autoimmune diseases, and genetic disorders. Founded in 2014 and headquartered in San Diego, California, the company built a pipeline around a proprietary allogeneic platform that derives cell therapies from healthy donor cells rather than from individual patients, with the intent of reducing per-patient cost and manufacturing timelines relative to autologous CAR-T approaches. Poseida's lead programs included P-BCMA-ALLO1 for multiple myeloma (positive Phase 1 interim data reported at ASH 2024), P-CD19CD20-ALLO1 as a dual-targeting candidate for B-cell malignancies, and P-MUC1C-ALLO1 for solid tumors.
The company's underlying technology stack combined non-viral gene editing (including transposase-based systems), proprietary gene insertion methods, and — via the Xyphos/Astellas collaboration — convertibleCAR architectures leveraging Xyphos' ACCEL technology. Poseida also held granted and pending patents on compositions targeting hemoglobin genes (hbg1/hbg2) and on transposases for genetic engineering and DNA amplification. The company was publicly traded on NASDAQ as PSTX prior to its acquisition.
Poseida's business model as an independent entity was R&D-driven and pre-commercial: it generated no product revenue and relied on equity financings (notably a $70M public offering in August 2022 and a $50M Astellas strategic investment in August 2023), strategic collaborations (Xyphos convertibleCAR deal valued at up to $550M in milestones plus tiered royalties), and eventual exit via M&A. Roche agreed to acquire Poseida for approximately $1.0 billion in cash (up to $1.5 billion with milestones) in November 2024 at a 215% premium, closing in Q1 2025; Poseida now operates as a wholly owned subsidiary integrated into Genentech's oncology, immunology, and neurology portfolio.
Poseida Therapeutics firmographics
Firmographics- Name
- Poseida Therapeutics
- Legal name
- Poseida Therapeutics, Inc.
- Website
- https://poseida.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- Poseida Therapeutics was a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies and gene editing technologies for hematologic malignancies, solid tumors, autoimmune diseases, and genetic disorders, acquired by Roche in 2025.
- Ownership category
- akta.pro rank
Poseida Therapeutics industry classification
Industry- Product category
- Cell Therapy / Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
Keywords
Where Poseida Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Poseida Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Marketing channels3 records
Poseida Therapeutics product offering
Product offeringCore offering
Poseida Therapeutics develops allogeneic (off-the-shelf) CAR-T cell therapy candidates for the treatment of multiple myeloma, B-cell malignancies, and solid tumors. The company uses proprietary non-viral gene editing and manufacturing platforms (piggyBac, Cas-CLOVER, and Ora) to engineer T-cell therapies intended for scalable, ready-to-use administration to patients.
Product overview
Poseida Therapeutics was a clinical-stage biopharmaceutical company focused on the development of allogeneic CAR-T cell therapies for cancer treatment. The company's product portfolio included multiple clinical-stage candidates: P-BCMA-ALLO1 for multiple myeloma, P-CD19CD20-ALLO1 as a dual CAR-T targeting B-cell malignancies, and P-MUC1C-ALLO1 for solid tumors. These programs were built on Poseida's proprietary allogeneic CAR-T platform technology. Poseida was acquired by Roche in late 2024 for up to $1.5 billion and is now integrated under Genentech.
Differentiator
Problem solved
Functional benefit
Products and services
- P-BCMA-ALLO1
Quantifiable outcome
- 23% increase in share price following $50M Astellas investment announcement
Companies that use Poseida Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Poseida Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Poseida Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- RochecoreRoche acquired Poseida Therapeutics for approximately $1.0 billion in cash with potential total deal value up to $1.5 billion including milestones. The acquisition gave Roche full control of Poseida's cell therapy candidates and platform technologies for oncology, immunology, and neurology.
- Xyphos Biosciences (Astellas Pharma)coreResearch collaboration and license agreement to develop convertibleCAR programs targeting solid-tumor cancers, combining Poseida's allogeneic CAR-T platform with Xyphos' ACCEL technology. Poseida received $50 million upfront payment plus potential development and sales milestones and contingency payments totaling up to $550 million, as well as low double-digit tiered royalties on net sales.
- Takeda PharmaceuticalminorPrior collaboration terminated in July 2023. Poseida was evaluating its gene therapy projects following the termination of this collaboration.
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
Poseida Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Bristol Myers Squibb: Owns Breyanzi (CD19 CAR-T) and Abecma (BCMA CAR-T). As the incumbent CAR-T commercial leader with overlapping targets, BMS represents both competitive threat and potential strategic acquirer profile.
- Gilead Sciences (Kite Pharma): Owns Yescarta and Tecartus CAR-T franchises—the dominant commercial CAR-T player. Direct competitor for heme-oncology CAR-T share and benchmark for allogeneic cost/value proposition.
- Novartis: Owns Kymriah, the first FDA-approved CAR-T. Long-standing Poseida investor (led Series C in 2019) and established biopharma with overlapping cell therapy strategic interests.
- Johnson & Johnson: Co-developed Carvykti (BCMA CAR-T) with Legend Biotech—a direct competitor to Poseida's P-BCMA-ALLO1 in multiple myeloma. Major incumbent validating the BCMA CAR-T opportunity.
Direct peers
- Allogene Therapeutics: Pure-play allogeneic CAR-T developer with overlapping pipeline in BCMA, CD19, and CD70 targets. The most direct competitor to Poseida's off-the-shelf CAR-T platform.
- CRISPR Therapeutics: Gene-edited allogeneic CAR-T developer with approved Casgevy (with Vertex) and clinical-stage CAR-T programs targeting BCMA and CD19—directly comparable platform technology and targets.
- Caribou Biosciences: Allogeneic CAR-T developer using CRISPR-based gene editing for off-the-shelf cell therapies, with clinical programs in B-cell malignancies overlapping Poseida's P-CD19CD20-ALLO1.
- Precision BioSciences: Allogeneic CAR-T developer using ARCUS gene editing platform; pursuing off-the-shelf CAR-T for oncology with similar allogeneic manufacturing approach.
- Cellectis: Pioneer of allogeneic CAR-T using TALEN gene editing; supplies platform to Allogene and Servier and is a direct technological comparable to Poseida's gene-edited allogeneic platform.
Emerging players
- Editas Medicine: Clinical-stage gene editing company with both in vivo (Casgevy via partnership) and ex vivo cell therapy programs, representing adjacent gene editing platform technology.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Poseida Therapeutics social profiles
Digital presencePoseida Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Poseida Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Poseida Therapeutics funding detail
Funding detailFunding overview
Funding rounds9 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Poseida Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Poseida Therapeutics
What does Poseida Therapeutics do?
Poseida Therapeutics develops allogeneic (off-the-shelf) CAR-T cell therapy candidates for the treatment of multiple myeloma, B-cell malignancies, and solid tumors. The company uses proprietary non-viral gene editing and manufacturing platforms (piggyBac, Cas-CLOVER, and Ora) to engineer T-cell therapies intended for scalable, ready-to-use administration to patients.
Is Poseida Therapeutics a public or private company?
Poseida Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Poseida Therapeutics founded?
Poseida Therapeutics was founded in 2014. It employs 251 to 500 people.
Where is Poseida Therapeutics based?
Poseida Therapeutics is headquartered in San Diego, United States, in the North America region.
Who are Poseida Therapeutics's main competitors?
Broad incumbents on record are Bristol Myers Squibb, Gilead Sciences (Kite Pharma), Novartis and Johnson & Johnson. Direct peers are Allogene Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Precision BioSciences and Cellectis. Editas Medicine is listed as an emerging player.
Does Poseida Therapeutics have an API?
No public API is recorded for Poseida Therapeutics.
What industry is Poseida Therapeutics in?
Poseida Therapeutics's product category is Cell Therapy / Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.